SCO-116 (except Eye/Skin)
Lung disease, MASH, Diabetic kidney disease
PreclinicalActive
Key Facts
Indication
Lung disease, MASH, Diabetic kidney disease
Phase
Preclinical
Status
Active
Company
About SCOHIA PHARMA
A Japanese bioventure developing innovative small molecule drugs for metabolic, cardiovascular, and renal diseases through a diversified pipeline and strategic collaborations.
View full company profile